Alex Mutebi

Jul 19, 2024 | digitalcommons.library.tmc.edu | Andrew Ip |Alex Mutebi |Tongsheng Wang |Monika Jun

INTRODUCTION: Despite new therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatments with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents continue to be commonly used. METHODS: This retrospective study utilized longitudinal data from 4226 real-world electronic health records to characterize outcomes in patients with R/R DLBCL.